Online inquiry

IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1093MR)

This product GTTS-WQ1093MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1093MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1677MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ2570MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ8502MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ2869MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ5135MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ11925MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ13157MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ7571MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW